Harrow (NASDAQ:HROW) Posts Quarterly Earnings Results, Beats Expectations By $0.14 EPS

Harrow (NASDAQ:HROW) posted its quarterly earnings data on Thursday. The company reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.14, Zacks reports. Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. The firm had revenue of $66.83 million during the quarter, compared to analyst estimates of $66.01 million.

Harrow Stock Down 6.0 %

HROW stock opened at $26.21 on Friday. The company has a 50 day moving average of $28.90 and a two-hundred day moving average of $38.01. The company has a market cap of $933.47 million, a price-to-earnings ratio of -27.88 and a beta of 0.69. Harrow has a 12-month low of $9.86 and a 12-month high of $59.23. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23.

Wall Street Analyst Weigh In

Several brokerages have recently commented on HROW. HC Wainwright reaffirmed a “buy” rating and issued a $57.00 target price on shares of Harrow in a research report on Tuesday, March 18th. B. Riley decreased their price objective on Harrow from $73.00 to $69.00 and set a “buy” rating for the company in a research report on Wednesday, December 4th.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.